

AD_____

GRANT NO:

DAMD17-94-J-4324

TITLE:

Role of eIF-2 α -specific protein kinase (PKR) in the proliferation of breast carcinoma cells

PRINCIPAL INVESTIGATOR:

Rosemary Jagus, Ph.D.

CONTRACTING ORGANIZATION:


**University of Maryland Biotechnology
Institute**
College Park, Maryland 20740

REPORT DATE:

7/29/95

TYPE OF REPORT:

Annual



PREPARED FOR:

U.S. Army Medical Research and Materiel
Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950925 145

DTIC QUALITY INSPECTED 5

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 29, 1995	3. REPORT TYPE AND DATES COVERED Annual 1 Jul 94 - 30 Jun 95	
4. TITLE AND SUBTITLE Role of eIF-2 α -Specific Protein Kinase (PKR) in the Proliferation of Breast Carcinoma Cells			5. FUNDING NUMBERS DAMD17-94-J-4324	
6. AUTHOR(S) Rosemary Jagus, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Maryland Biotechnology Institute College Park, Maryland 20740			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) <p>Levels of the eIF-2α-specific protein kinase, PKR, are higher in several breast carcinoma cell lines including the estrogen-responsive cell lines, MCF-7 and T-47D, as well as estrogen-independent cell lines, BT-20 and MDA-MB-468, compared with the normal breast cell line, Hs578 Bst, or the human HeLa cell line. In contrast, the phosphorylation state of eIF-2α is very low in the breast carcinoma cell lines compared to the normal human breast cell line Hs578 Bst and HeLa cells, even at high cell densities, suggesting an inhibition of PKR activity in the breast carcinoma cell lines. In support of this hypothesis, treatment of cells with either α- or β-interferon, although increasing PKR levels slightly, do not result in higher steady state levels of eIF-2α phosphorylation.</p> <p>These results suggest that deregulation of PKR activity is occurring at some level in breast carcinoma cell lines. This deregulation could result from increased levels/activities of cellular PKR inhibitory proteins, or from inactivating mutations in the PKR gene. These results are consistent with the putative role of PKR as a tumor suppressor gene and in accordance with the idea that activation of the translational machinery may be one mechanism through which oncogenes exert their transforming function.</p>				
14. SUBJECT TERMS PKR; Protein Synthesis; Control of Proliferation			15. NUMBER OF PAGES 8	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

Block 1. Agency Use Only (Leave blank).

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

Block 13. Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code (*NTIS only*).

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

NA Where copyrighted material is quoted, permission has been obtained to use such material.

NA Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

NA Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

NA In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

RJ ✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

RJ ✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

RJ ✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

RJ ✓ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Rosmary J. J. J. 7/29/95
PI - Signature Date

TABLE OF CONTENTS

INTRODUCTION:	2
BODY:	2
CONCLUSIONS:	3
PERSONNEL FUNDED	3
PUBLICATIONS ARISING FROM AWARD	4
REFERENCES:	4

APPENDIX: Savinova O. and Jagus, R.: Deregulation of the interferon induced, dsRNA activated protein kinase, PKR, in breast carcinoma cells. Interferon and Cytokine Research, in press, 1995.

Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification _____	
By _____	
Distribution /	
Availability Codes	
Dist	Avail and / or Special
A-1	

INTRODUCTION

This grant represents an innovative developmental and exploratory award to an investigator who had no previous background in human breast cancer, but who has a long history in the study of protein synthesis regulation and its role in the regulation of cell proliferation. The investigator seeks to investigate the possibility that aberrant regulation of cellular protein synthesis could underlie the loss of growth control in breast carcinoma cells through dysfunction of the dsRNA activated, eIF-2 α -specific protein kinase, PKR. This kinase has been implicated as a tumor suppressor gene, because of its growth suppressive and translational inhibitory properties, as well as the ability of nonfunctional mutants of PKR to transform cells [1]. The role of PKR, in the loss of growth control in breast cancer cells has been investigated by a comparison of the expression and regulation of activity of PKR in normal breast and breast carcinoma cell lines. Furthermore, an evaluation of the role of PKR in the the estrogen responsiveness of breast carcinoma cell lines has been made by a comparison of PKR expression, and regulation of activity, in an estrogen responsive line treated with or without estrogen, or the estrogen antagonist, tamoxifen. Monoclonal antibodies are available to human PKR and have been used for the determination of PKR levels and phosphorylation (activation) state. The state of PKR activation has also be determined by an analysis of the phosphorylation state of its substrate, eIF-2 α .

BODY

Four tasks were outlined in the **Statement of Work** in the application. These were:

1. Analysis of PKR expression in breast carcinoma tissue.
2. Analysis of PKR expression in breast carcinoma cell lines.
3. Analysis of the effect of estrogen antagonists on the regulation of PKR expression/activity in estrogen receptor positive breast carcinoma cell lines.
4. Analysis of PKR expression/activity in cell lines stably transformed with the human placental aromatase gene and effects of aromatase inhibitors.

Tasks 2 and 3 analyzing the characteristics of breast carcinoma cell lines have been completed. Over a range of cell densities, eIF-2 α levels, PKR levels, PKR activation state and eIF-2 α phosphorylation state has been monitored in two estrogen receptor positive cell lines, MCF7 and T47D, and two estrogen unresponsive cell lines, BT-20 and MDA-MB-468. These have been compared to the same parameters in a normal human breast cell line, Hs578 Bst. The results with breast carcinoma cell lines have also been compared to those obtained in the human HeLa fibroblast cell line, since much is known about the regulation of PKR expression/regulation in this system.

Levels of the protein synthesis initiation factor, eIF-2 α are 2-3 fold higher in the human breast carcinoma cell lines compared to the normal human breast cell line and the HeLa cell line. To some extent this parallels the increased ribosome content (1.5-2 fold higher), although eIF-2 α :ribosome ratios are higher in breast carcinoma cells compared to normal human breast cell lines. This is consistent with the increased protein synthetic activity necessary to sustain higher proliferation rates. It is also

consistent with the raised *c-myc* levels of breast carcinoma cells which increases the expression of eIF-2 α [2]. In addition, levels of the eIF-2 α -specific protein kinase, PKR, are also much higher in breast carcinoma cell lines compared with Hs578 Bst or HeLa cells. PKR levels in breast carcinoma cells are approximately equimolar with ribosomes, whereas in HeLa cells the equivalent level is 1 molecule of PKR for every 4-5 ribosomes [3]. In contrast to this, the phosphorylation state of eIF-2 α is very low in the breast carcinoma cell lines compared to the normal human breast cell line Hs578 Bst and HeLa cells, even at high cell densities. In HeLa, PKR activity increases with increasing PKR levels. In HeLa and normal breast cells, eIF-2 α phosphorylation state increases with increasing cell density. The high levels of PKR in breast carcinoma cells, in conjunction with low eIF-2 α phosphorylation levels, suggests an inhibition of PKR activity in the breast carcinoma cell lines. Consistent with this hypothesis, treatment of cells with either α - or β -interferon increased PKR levels slightly, but did not result in higher steady state levels of eIF-2 α phosphorylation. Similarly, incubation of breast carcinoma cells with dsRNA after interferon treatment did not result in higher steady state levels of eIF-2 α phosphorylation. Interestingly, a combination of β -interferon and retinoic acid gave rise to increased levels of PKR mRNA, which was not reflected in increased levels of PKR.

In the estrogen receptor positive cell lines, estrogen removal or re-addition had no effects on PKR levels/activities. Furthermore, estrogen removal or re-addition had no effects on eIF-2 α phosphorylation levels or phosphorylation state.

CONCLUSIONS

These results are consistent with the deregulation of PKR activity in breast carcinoma cell lines which could result from increased levels/activities of PKR inhibitory proteins or from inactivating mutations in the PKR gene. These results are consistent with the putative role of PKR as a tumor suppressor gene. The next step will be the analysis of PKR levels/activity in breast tumor samples. After confirmation of the results in tumors, the underlying mechanism(s) will be sought. Initially, analysis of the PKR gene will be pursued using a multiplex polymerase chain reaction amplification system that will reveal small deletions and insertions [4]. If the high PKR levels and low activities do not reflect nonfunctional mutations, it will be assumed that some element of the PKR regulatory cascade is dysfunctional. The initial assessment of this will be to assay for PKR inhibitory activity in breast carcinoma cell lines. In addition, levels of known cellular PKR inhibitors such as p58 [1,5] will be determined.

Knowledge of PKR regulation in breast carcinoma cells will allow us to pose some different questions on the interactions between hormones, growth factors, and cytokines. Furthermore, an understanding of PKR regulation in breast carcinoma cells should suggest what therapeutic agents might be effective in suppressin/reducing the growth of breast carcinomas.

Personnel funded by award: Olga Savinova, M.S. began work in the laboratory October, 1994.

Publications arising from funding: Savinova O. and Jagus, R.: Deregulation of the interferon induced, dsRNA activated protein kinase, PKR, in breast carcinoma cells. Interferon and Cytokine Research, 1995, in press.

REFERENCES

1. Jagus, R. and Gray, M. M. (1994) Proteins that interact with PKR. *Biochimie* **76**, 779-791.
2. Rosenwald, I. B., Rhoads, D. B., Callahan, L. D., Isselbacher, K. J., and Schmidt, E. V. (1993) Increased expression of eukaryotic translation factors eIF-4E and eIF-2 α in response to growth induction by *c-myc*. *PNAS* **90**, 6175-6178.
3. Jeffrey, I., Kadereit, S., Meurs, E. F., Metzger, T., Schwemmle, M., Bachmann, M., Hovanessian, A. G., and Clemens, M. Localization of PKR in human and transfected mouse cells. *Exptl. Cell Res.* **218**, 17-27.
4. Runnebaum, I. B., Nagarajan, M., Bowman, M., Soto, D., and Sukumar, S. (1991) Mutations in p53 as potential molecular markers for human breast cancer. *PNAS* **88**, 10657-10661.
5. Lee, T. G., Tomita, J., Hovanessian, A. G., and Katze, M. G. (1992) Characterization and regulation of the 58 kDa cellular inhibitor of PKR. *J. Biol. Chem.* **267**, 14238-14243.



ABSTRACT FORM

RETURN BEFORE
JUNE 15, 1995.



INTERNATIONAL SOCIETY
FOR INTERFERON AND CYTOKINE RESEARCH
Post Office Box 22478
Cleveland, OH 44122
U.S.A.
Phone: (216) 464-2055 FAX: (216) 464-3884

Abstract must fit inset area of this form. All abstracts must be submitted on an original abstract form (please do not fold). Text must be written in English and single-spaced using black ribbon. **DO NOT USE A DOT-MATRIX PRINTER.** Title must be typed in capital letters. The speaker's name should be underlined. Indicate where research was done.

DEREGULATION OF THE INTERFERON INDUCED, dsRNA ACTIVATED PROTEIN KINASE, PKR, in BREAST CARCINOMA CELLS

Olga Savinova and Rosemary Jagus, Center of Marine Biotechnology, UMBI, Baltimore,
MD 21202

Levels of the protein synthesis initiation factor, eIF-2 α are higher in the human breast carcinoma cell lines, MCF-7 and T-47D compared to the normal human breast cell line Hs578 Bst. This is consistent with the increased protein synthetic activity necessary to sustain higher proliferation rates. In addition, the phosphorylation state of eIF-2 α is very low in the breast carcinoma cell lines compared to the normal human breast cell line Hs578 Bst and the mouse fibroblast cell line, NIH3T3, even at high cell densities. Surprisingly, levels of the eIF-2 α -specific protein kinase, PKR, are also much higher in MCF-7 and T-47D cell lines compared with Hs578 Bst or 3T3 cells, suggesting an inhibition of PKR activity in the breast carcinoma cell lines. In support of this hypothesis, treatment of cells with either α - or β -interferon, although increasing PKR levels slightly, do not result in higher steady state levels of eIF-2 α phosphorylation.

These results suggest that deregulation of PKR activity is occurring at some level in breast carcinoma cell lines. This deregulation could result from increased levels/activities of cellular PKR inhibitory proteins, or from inactivating mutations in the PKR gene. These results are consistent with the putative role of PKR as a tumor suppressor gene and in accordance with the idea that activation of the translational machinery may be one mechanism through which oncogenes exert their transforming function.

Speaker's phone number: () _____ FAX number () _____
Preference: ☐ Oral ☐ Poster ☐ Either

TOPIC AREA

(Please choose a subject category from each of the two lists below)

PLENARY SESSIONS

- ☐ P1 - Signal Transduction and Structure and Function of Receptors for Interferons and Cytokines
- ☐ P2 - Gene Regulation
- ☐ P3 - Cytokines as Modulators of the Immune System
- ☐ P4 - Role of Cytokines in Oncology
- ☐ P5 - Cytokine Network in Infectious Diseases

WORKSHOPS

- ☐ W1 - Receptor Structure and Properties, Soluble Receptors, and Receptor Antagonists
- ☐ W2 - Signal Transduction
- ☐ W3 - Molecule Mechanisms of Cytokine Gene Regulation
- ☐ W4 - Biological Role of Interferon-Induced Enzymes
- ☐ W5 - Cytokine Crosstalk
- ☐ W6 - Cytokine in Anticancer Therapy
- ☐ W7 - Role of Cytokines in Macrophage Biology
- ☐ W8 - Cytokines in Pathogenicity and Treatment of Infections and Neurological Diseases

For reviewer's use: Pre-Approved # _____ ☐ Plenary ☐ Workshop ☐ Poster
Approved Abstract # _____